These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22555836)

  • 1. Safety and efficacy of Adalimumab in the treatment of moderate to severe palmo-plantar psoriasis: an open label study.
    Richetta AG; Mattozzi C; Giancristoforo S; D'Epiro S; Cantisani C; Macaluso L; Salvi M; Calvieri S
    Clin Ter; 2012; 163(2):e61-6. PubMed ID: 22555836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C; Langley RG; Papp K; Tyring SK; Wasel N; Vender R; Unnebrink K; Gupta SR; Valdecantos WC; Bagel J
    Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept.
    Bissonnette R; Bolduc C; Poulin Y; Guenther L; Lynde CW; Maari C
    J Am Acad Dermatol; 2010 Aug; 63(2):228-34. PubMed ID: 20494479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.
    Bagel J
    J Drugs Dermatol; 2011 Apr; 10(4):366-71. PubMed ID: 21455546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
    Papp K; Crowley J; Ortonne JP; Leu J; Okun M; Gupta SR; Gu Y; Langley RG
    Br J Dermatol; 2011 Feb; 164(2):434-41. PubMed ID: 21083543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA
    J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness and safety of adalimumab in the treatment of non-reimbursed patients with mild-to-moderate psoriasis.
    Chiu HY; Wang TS; Chang CY; Tsai TF
    J Eur Acad Dermatol Venereol; 2012 Aug; 26(8):991-8. PubMed ID: 21812835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study.
    Papp K; Ho V; Teixeira HD; Guerette B; Chen K; Lynde C
    J Eur Acad Dermatol Venereol; 2012 Aug; 26(8):1007-13. PubMed ID: 22023702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.
    Strober BE; Poulin Y; Kerdel FA; Langley RG; Gu Y; Gupta SR; Okun MM; Papp KA
    J Am Acad Dermatol; 2011 Apr; 64(4):671-81. PubMed ID: 21414495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
    J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP; Chimenti S; Reich K; Gniadecki R; Sprøgel P; Unnebrink K; Kupper H; Goldblum O; Thaçi D
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
    Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
    Gordon K; Papp K; Poulin Y; Gu Y; Rozzo S; Sasso EH
    J Am Acad Dermatol; 2012 Feb; 66(2):241-51. PubMed ID: 21752491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
    Noda S; Mizuno K; Adachi M
    J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM
    J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
    N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
    Strober BE; Sobell JM; Duffin KC; Bao Y; Guérin A; Yang H; Goldblum O; Okun MM; Mulani PM
    Br J Dermatol; 2012 Dec; 167(6):1374-81. PubMed ID: 22897348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
    Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
    Elewski BE; Okun MM; Papp K; Baker CS; Crowley JJ; Guillet G; Sundaram M; Poulin Y; Gu Y; Geng Z; Williams DA; Rich PA
    J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.